+224.0%
AXP vs MRNA
+806.0%
-582.1%
-49.6%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 10y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -1.4% | +1.3% | -2.7% | -1.4% |
| 7D | -2.2% | -13.8% | +11.7% | -1.9% |
| 30D | -2.3% | -17.7% | +15.4% | -1.9% |
| 3M | -8.2% | +14.3% | -22.5% | -8.7% |
| 6M | +1.2% | +336.0% | -334.8% | -4.6% |
| YTD | -15.0% | +575.9% | -590.9% | -21.1% |
| 1Y | -8.7% | +724.4% | -733.1% | -15.9% |
| 3Y | +98.0% | +160.8% | -62.8% | +85.0% |
| 5Y | +90.6% | -24.4% | +115.1% | +75.5% |
| All | +224.0% | +806.0% | -582.1% | +226.9% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 10y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
10y analysis · Full analysis span regression · 6 months rolling